PT-141

PT-141, also known as Bremelanotide, is a synthetic peptide and a research compound primarily investigated for its effects on sexual dysfunction. It is a melanocortin receptor agonist, specifically targeting melanocortin receptors 3 and 4, which are involved in various physiological processes, including sexual arousal. Unlike other treatments for sexual dysfunction, such as Viagra, which primarily act on vascular mechanisms, PT-141 works through the central nervous system, influencing sexual desire and arousal.

In preclinical and clinical studies, PT-141 has shown potential in improving libido and sexual performance in both men and women, particularly in those with conditions like erectile dysfunction and hypoactive sexual desire disorder (HSDD). It is typically administered through subcutaneous injection, and its effects can occur within a few hours of administration.

While PT-141 has demonstrated promise in early-stage research, it is still under investigation, and its long-term safety, efficacy, and regulatory status remain subjects of ongoing studies. Researchers continue to explore its potential applications in treating various sexual disorders, as well as other areas such as obesity and mood disorders.